SenesTech Business Summary

SenesTech, Inc. (SNES) is a biotechnology pioneer specializing in sustainable rodent fertility control, generating revenue through the sale of its proprietary EPA-registered contraceptives, ContraPest® and Evolve®. The company’s business model is centered on three primary segments: E-commerce (accounting for over 50% of 2025 revenue via Amazon, Home Depot, and Lowe’s), Commercial/Distributor channels (leveraging international partnerships in New Zealand and India), and Municipal/Professional field sales. As of early 2026, the Evolve® product line drives approximately 85% of total revenue, with a strategic shift toward internal management of Amazon sales to enhance gross margins. SenesTech competes against traditional rodenticide giants like Neogen Corporation, Bell Laboratories, and Syngenta AG, positioning itself as the niche leader in non-lethal, integrated pest management (IPM) solutions that suppress populations by disrupting reproductive cycles. Founded in 2004 by Dr. Loretta Mayer and Dr. Cheryl Dyer based on their rodent menopause research at Northern Arizona University, SenesTech is currently led by President and CEO Joel Fruendt, who is slated to retire by June 30, 2026. To ensure a stable transition, the Board appointed Dr. Jamie Bechtel as Interim Executive Chair and Michael Edell as Interim COO, working alongside long-standing CFO Tom Chesterman. The company’s scientific direction is spearheaded by Courtney Ray, VP of Science & Innovation. SenesTech maintains a notable investor base including Glenbrook Capital Management and Sabby Management LLC, with a Board of Directors that includes Vice Chair Matthew K. Szot and Dexcom COO Jake Leach, all focused on achieving the company's projected cash flow breakeven by late 2026.